Controlled afib
Pro Research Analysisby 
Searched over 200M research papers for "controlled afib"
Controlled Atrial Fibrillation: Insights and Management Strategies
Early Detection and Intervention for Atrial Fibrillation
Keywords: Early Detection, Atrial Fibrillation, Intervention
Early detection and timely intervention are crucial in managing atrial fibrillation (AFib) to prevent severe complications such as stroke and heart failure. A study tested the feasibility of the "Alert for AFib" intervention, which aimed to improve knowledge, attitudes, and beliefs about seeking treatment for AFib symptoms among adults aged 65 and older. The intervention group showed significant improvements in knowledge (p = .005) and attitudes (p < .001) about treatment-seeking compared to the control group, suggesting that such interventions could be effective in larger trials .
Role of Transesophageal Echocardiography in Cardioversion
Keywords: Transesophageal Echocardiography, Cardioversion, Thromboembolic Complications
Cardioversion, a common treatment for AFib, can be performed using medications (pharmacological cardioversion) or electrical shock (electric cardioversion). However, electric cardioversion (ECV) carries risks of thromboembolic complications, such as embolic strokes. Transesophageal echocardiography (TEE) is a critical tool used to identify potential embolic sources before cardioversion, thereby reducing the risk of such complications. A comprehensive review of 36 studies confirmed that TEE is instrumental in preventing thromboembolic events during ECV for AFib, although further research is needed to explore this area more thoroughly .
Risks Associated with Ibrutinib Treatment
Keywords: Ibrutinib, Atrial Fibrillation, Bleeding Risk
Ibrutinib, a treatment for hematologic malignancies, has been associated with an increased risk of atrial fibrillation/flutter (AFib/Aflutter) and bleeding. A systematic review and pooled analysis of four randomized controlled trials revealed that patients treated with ibrutinib had significantly higher incidences of serious AFib/Aflutter (3.03% vs. 0.80%) and all-grade AFib/Aflutter (8.18% vs. 0.93%) compared to control treatments. Additionally, the risk of all-grade bleeding was also higher in the ibrutinib group (4.85% vs. 1.55%). These findings highlight the need for vigilant monitoring and careful assessment of anticoagulation risks and benefits in patients receiving ibrutinib therapy .
Conclusion
Effective management of atrial fibrillation involves early detection, appropriate intervention, and careful monitoring of treatment-related risks. Interventions like the "Alert for AFib" can significantly improve patient outcomes by enhancing knowledge and attitudes towards treatment-seeking. Tools like transesophageal echocardiography are essential in mitigating the risks associated with cardioversion. Additionally, treatments such as ibrutinib require careful consideration due to their associated risks of AFib and bleeding. Continued research and vigilant clinical practices are necessary to optimize AFib management and improve patient safety.
Sources and full results
Most relevant research papers on this topic